CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (VRTX) reported a fourth-quarter net loss to company of $176.66 million or $0.74 per share, compared to profit of $44.29 million or $0.19 per share, prior year. Adjusted loss per share was $0.55, for the quarter.
On average, 16 analysts polled by Thomson Reuters expected the company to report loss per share of $0.65 for the quarter. Analysts' estimates typically exclude special items.
Revenue decreased to $144.56 million from $351.16 million last year. Non-GAAP total revenues were $140.59 million, for the quarter. Analysts expected revenue of $137.49 million for the quarter.
Vertex expects KALYDECO net revenues of $560 to $580 million for 2015.
Copyright RTT News/dpa-AFX